HCPCS Code Applications and Approvals: October 2026
Quarterly archive · CMS Level II HCPCS42 coding decisions took effect October 1, 2026
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Second Quarter 2026 coding cycle, which took effect October 1, 2026.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
October 2026
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| A9595 | PYLARIFY TRUVU 505(b)(2) Piflufolastat f 18 (pylarify), diagnostic, 1 millicurie | Lantheus Medical Imaging, Inc. Intravenous | — | Revise | |
| A9613 | PYLARIFY TRUVU 505(b)(2) Piflufolastat f 18 (pylarify truvu), diagnostic, 1 millicurie | Lantheus Medical Imaging, Inc. Intravenous | — | Establish | |
| C9046 | GOPRELTO 505(b)(2) Cocaine hydrochloride nasal solution (goprelto), 1 mg | LXO US Intranasal | Replaced byJ0014 | Discontinue | |
| C9310 | VYKOURA 505(b)(2) Injection, leucovorin calcium (avyxa), 1 mg | Avyxa Pharma LLC Intramuscular | Replaced byJ0644 | Discontinue | |
| C9462 | Baxdela Injection, delafloxacin, 1 mg | CorMedix Therapeutics Intravenous/Oral | Replaced byJ3268 | Discontinue | |
| J0014 | GOPRELTO 505(b)(2) Cocaine hydrochloride nasal solution (goprelto), 1 mg | LXO US Intranasal | ReplacesC9046 | Establish | |
| J0640 | Leucovorin Calcium Leucovorin calcium, 50 mg | — | Replaced byJ0643 | Discontinue | |
| J0643 | Leucovorin Calcium Injection, leucovorin calcium, not otherwise specified, 1 mg | — | ReplacesJ0640 | Establish | |
| J0644 | VYKOURA 505(b)(2) Injection, leucovorin calcium (avyxa), 1 mg | Avyxa Pharma LLC Intramuscular | ReplacesC9310 | Establish | |
| J0871 | Daptomycin (Endo) 505(b)(2) Injection, daptomycin (endo), not therapeutically equivalent to j0878, 1 mg | Endo Pharmaceuticals Intravenous | — | Establish | |
| J1757 | AVLAYAH Injection, tividenofusp alfa-eknm, 1 mg | Denali Therapeutics Inc. Intravenous | — | Establish | |
| J1818 | Loargys Injection, pegzilarginase-nbln, 0.05 mg | Immedica USA Inc. Intravenous | — | Establish | |
| J1941 | Furosemide (Furoscix) Injection, furosemide (furoscix), 20 mg | — | Replaced byJ1947 | Discontinue | |
| J1946 | Lasix ONYU Injection, furosemide (lasix onyu), 1 mg | SQ Innovation Inc. Subcutaneous | — | Establish | |
| J1947 | Furosemide (Furoscix) 505(b)(2) Injection, furosemide (furoscix), 1 mg | — | ReplacesJ1941 | Establish | |
| J1953 | Levetiracetam Injection, levetiracetam, 10 mg | — | Replaced byJ1957 | Discontinue | |
| J1957 | Levetiracetam Injection, levetiracetam, 5 mg | — | ReplacesJ1953 | Establish | |
| J1958 | Levetiracetam In Sodium Chloride Injection, levetiracetam in sodium chloride, 5 mg | — | — | Establish | |
| J3268 | Baxdela Injection, delafloxacin, 1 mg | CorMedix Therapeutics Intravenous/Oral | ReplacesC9462 | Establish | |
| J3300 | Triamcinolone Acetonide (Triesence) Injection, triamcinolone acetonide (triesence), preservative free, 1 mg | — | — | Revise | |
| J3406 | OMISIRGE Injection, omidubicel-onlv, per therapeutic dose | Gamida Cell Intravenous | — | Establish | |
| J7514 | Mycophenolate Mofetil (Myhibbin) Mycophenolate mofetil (myhibbin), oral suspension, 100 mg | — | Replaced byJ7530 | Discontinue | |
| J7517 | Mycophenolate Mofetil Mycophenolate mofetil, oral, 250 mg | — | Replaced byJ7524 | Discontinue | |
| J7519 | Mycophenolate Mofetil Injection, mycophenolate mofetil, 10 mg | — | Replaced byJ7526 | Discontinue | |
| J7524 | Mycophenolate Mofetil Mycophenolate mofetil, oral, 5 mg | — | ReplacesJ7517 | Establish | |
| J7526 | Mycophenolate Mofetil Injection, mycophenolate mofetil, 5 mg | — | ReplacesJ7519 | Establish | |
| J7528 | Mycophenolate Mofetil Mycophenolate mofetil, for suspension, oral, 100 mg | — | Replaced byJ7529 | Discontinue | |
| J7529 | Mycophenolate Mofetil Mycophenolate mofetil, for suspension, oral, 5 mg | — | ReplacesJ7528 | Establish | |
| J7530 | Mycophenolate Mofetil (Myhibbin) 505(b)(2) Mycophenolate mofetil (myhibbin), oral suspension, 5 mg | — | ReplacesJ7514 | Establish | |
| J7531 | Prednisolone Sodium Phosphate Prednisolone sodium phosphate, orally disintegrating tablet, 1 mg | — | — | Establish | |
| J9033 | Bendamustine Hydrochloride Injection, bendamustine hydrochloride, not otherwise specified, 1 mg | — | — | Revise | |
| J9066 | Bendamustine Hydrochloride Injection 505(b)(2) Injection, bendamustine hydrochloride (avyxa), 1 mg | AVYXA Pharma, LLC Intravenous | — | Establish | |
| J9181 | Etoposide Injection, etoposide, 10 mg | — | Replaced byJ9187 | Discontinue | |
| J9186 | AVOPEF 505(b)(2) Injection, etoposide (avyxa), 1 mg | AVYXA Pharma, LLC Intravenous | — | Establish | |
| J9187 | Etoposide injection, etoposide, 1 mg | — | ReplacesJ9181 | Establish | |
| J9190 | Fluorouracil Injection, fluorouracil, 500 mg | — | Replaced byJ9192 | Discontinue | |
| J9191 | FAVLYXA 505(b)(2) Injection, fluorouracil (avyxa), 10 mg | AVYXA Pharma, LLC Intravenous | — | Establish | |
| J9192 | Fluorouracil Injection, fluorouracil, 10 mg | — | ReplacesJ9190 | Establish | |
| J9352 | Trabectedin Injection, trabectedin, 0.1 mg | — | Replaced byJ9362 | Discontinue | |
| J9362 | Trabectedin 505(b)(2) Injection, trabectedin, 0.01 mg | — | ReplacesJ9352 | Establish | |
| Q5172 | FILKRI Biosimilar Injection, filgrastim-laha (filkri), biosimilar, 1 microgram | Accord Biopharma Subcutaneous/Intravenous | — | Establish | |
| Q5173 | PONLIMSI Biosimilar Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg | Teva Pharmaceuticals Subcutaneous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Second Quarter 2026 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
